Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death.

Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG, Véniant M, Dichek DA.

Circulation. 2004 May 4;109(17):2129-35.

2.

Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.

Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA.

Circ Res. 2004 Sep 17;95(6):637-44.

3.

Paradoxical effect on atherosclerosis of hormone-sensitive lipase overexpression in macrophages.

Escary JL, Choy HA, Reue K, Wang XP, Castellani LW, Glass CK, Lusis AJ, Schotz MC.

J Lipid Res. 1999 Mar;40(3):397-404.

4.

Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator.

Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G, Dichek DA.

J Biol Chem. 2006 Jun 2;281(22):15345-51.

5.

Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice.

Kremen M, Krishnan R, Emery I, Hu JH, Slezicki KI, Wu A, Qian K, Du L, Plawman A, Stempien-Otero A, Dichek DA.

Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17109-14. doi: 10.1073/pnas.0808650105.

6.
7.

Reduction of mouse atherosclerosis by urokinase inhibition or with a limited-spectrum matrix metalloproteinase inhibitor.

Hu JH, Touch P, Zhang J, Wei H, Liu S, Lund IK, Høyer-Hansen G, Dichek DA.

Cardiovasc Res. 2015 Mar 1;105(3):372-82. doi: 10.1093/cvr/cvv007.

8.

Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins.

Farris SD, Hu JH, Krishnan R, Emery I, Chu T, Du L, Kremen M, Dichek HL, Gold E, Ramsey SA, Dichek DA.

J Biol Chem. 2011 Jun 24;286(25):22665-77. doi: 10.1074/jbc.M110.202135.

9.
10.

Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.

Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg D.

Blood. 2000 Dec 15;96(13):4212-5.

11.

Urokinase-type plasminogen activator plays a critical role in angiotensin II-induced abdominal aortic aneurysm.

Deng GG, Martin-McNulty B, Sukovich DA, Freay A, Halks-Miller M, Thinnes T, Loskutoff DJ, Carmeliet P, Dole WP, Wang YX.

Circ Res. 2003 Mar 21;92(5):510-7.

12.

Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.

Gu JM, Johns A, Morser J, Dole WP, Greaves DR, Deng GG.

J Cell Physiol. 2005 Jul;204(1):73-82.

PMID:
15573379
13.
14.

Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice.

Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, Kindt EK, Homan R, Karathanasis SK, Rekhter MD.

Circulation. 2004 Nov 30;110(22):3465-71.

15.

Overexpression of urokinase by plaque macrophages causes histological features of plaque rupture and increases vascular matrix metalloproteinase activity in aged apolipoprotein e-null mice.

Hu JH, Du L, Chu T, Otsuka G, Dronadula N, Jaffe M, Gill SE, Parks WC, Dichek DA.

Circulation. 2010 Apr 13;121(14):1637-44. doi: 10.1161/CIRCULATIONAHA.109.914945.

16.

Macrophage apolipoprotein E reduces atherosclerosis and prevents premature death in apolipoprotein E and scavenger receptor-class BI double-knockout mice.

Yu H, Zhang W, Yancey PG, Koury MJ, Zhang Y, Fazio S, Linton MF.

Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):150-6.

17.

Endothelial overexpression of Fas ligand decreases atherosclerosis in apolipoprotein E-deficient mice.

Yang J, Sato K, Aprahamian T, Brown NJ, Hutcheson J, Bialik A, Perlman H, Walsh K.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1466-73.

18.

Lack of urokinase plasminogen activator promotes progression and instability of atherosclerotic lesions in apolipoprotein E-knockout mice.

Dellas C, Schremmer C, Hasenfuss G, Konstantinides SV, Schäfer K.

Thromb Haemost. 2007 Jul;98(1):220-7.

PMID:
17598016
19.

Urokinase-type plasminogen activator and macrophages are required for skeletal muscle hypertrophy in mice.

DiPasquale DM, Cheng M, Billich W, Huang SA, van Rooijen N, Hornberger TA, Koh TJ.

Am J Physiol Cell Physiol. 2007 Oct;293(4):C1278-85.

20.

Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism.

Fuhrman B, Khateeb J, Shiner M, Nitzan O, Karry R, Volkova N, Aviram M.

Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1361-7. doi: 10.1161/ATVBAHA.108.166041.

Items per page

Supplemental Content

Support Center